Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

mirdametinib 1Everolimus 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Arteriovenous Malformations × Everolimus × Clear all
NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Yonsei University

Phase 2 Not yet recruiting
67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡